Fapon Biopharma and MOTE Therapeutics Unveil B-Cell Immunotherapy Strategy at BIO 2026

Introduction

Fapon Biopharma and MOTE Therapeutics are set to showcase their groundbreaking B-cell immunotherapy franchise at the upcoming BIO International Convention 2026, happening from June 22 to 25 at the San Diego Convention Center. Both companies, part of the Fapon Group, will be jointly exhibiting their innovative solutions for B-cell depletion which promises to change the landscape of immunotherapy.

Presenting Dual-Platform Innovations

The highlight of their presentation will be a dual-targeting strategy focusing on CD19 and BCMA using a dual-platform approach that combines T-cell engagers (TCEs) with in vivo CAR-T therapies. This dual-platform method aims at achieving profound and long-lasting B-cell depletion through complementary therapeutic modalities. Both products are expected to advance into human trials within the next six months, marking a significant step in clinical immunology.

Highlighted Programs at BIO 2026

Fapon and MOTE will exhibit at Booth 5435-2 in the Shanghai Pudong Pavilion, providing insights into their cutting-edge technology platforms and diverse pipeline targeting immuno-oncology and autoimmune diseases. The main focus will be two unique programs, FPE024—a tri-specific TCE targeting CD19 and BCMA—and MTX001, which utilizes MOTE's mobilize™ technology for a next-generation CAR-T approach. FPE024 aims for an Investigational New Drug (IND) filing targeted for Q1 2027, while MTX001 is expected to commence a first-in-human trial by Q4 2026.

Proprietary Platforms Driving Innovation

The backbone of their B-cell depletion franchise is built on proprietary technology platforms that each company possesses. Fapon Biopharma’s TCE platform enables human-cynomolgus cross-reactivity and scalable manufacturing. On the other hand, MOTE Therapeutics' mobilize™ platform allows for efficient RNA payload delivery systems that enhance specificity and efficacy in targeting therapeutics—a feat that has been challenging in the nucleic acid medicine field.

Expansion of Clinical Pipeline

Beyond B-cell depletion strategies, both firms are pioneering several other therapeutic candidates. Fapon is leading with FP008, a PD1×IL10M fusion protein currently in Phase I, with significant readouts anticipated in 2026. FP012 targets inflammatory bowel disease and other sequelae, while FPE021 focuses on gastrointestinal cancers. Moreover, FP012 and FPE021 are entering critical IND-enabling stages, showcasing the dynamic growth of their pipeline.

Engaging with the Community

At BIO 2026, attendees will have the unique opportunity to engage with Fapon and MOTE during a dedicated presentation titled, "Building a Dual-Targeting / Dual-Platform Franchise for B-Cell Immunotherapy," scheduled for Monday, June 22 at 4:30 PM PT in Room 3. This session aims to delve into the technological innovations, development roadmaps, and commercial potential of the companies’ integrated approach to B-cell therapy.

Partnership Opportunities

Fapon Biopharma and MOTE Therapeutics are keen on forging flexible partnership models, including co-development and licensing, with industry stakeholders. Interested parties can schedule one-on-one meetings in advance or join the companies at Booth 5435-2 during exhibit hours to explore collaborative opportunities and discuss how these innovative platforms can aid in the pursuit of next-generation therapies.

Conclusion

With their innovative approaches and robust pipeline, Fapon Biopharma and MOTE Therapeutics are making significant strides towards advancing B-cell immunotherapies. Their participation at BIO 2026 not only highlights their commitment toward improving patient outcomes but also underscores the potential of collaborative efforts within the biotechnology landscape. Attendees looking to redefine their professional networking in this pivotal area of health technology should not miss this opportunity.